Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells

ZONG-GANG XIE*, YE XIE* and QI-RONG DONG

Department of Orthopedic Surgery, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215006, P.R. China

Received January 7, 2013; Accepted June 27, 2013

DOI: 10.3892/ol.2013.1531

Abstract. It has been well documented that the inhibition of the mammalian target of rapamycin (mTOR) induces autophagy in proliferative cells. Therefore, mTOR inhibitors have been proposed for the treatment of cancer. As autophagy plays significant roles in tumor cell survival, the present study aimed to investigate the contribution of autophagy activation to the antitumor effects of cis-diamminedichloroplatinum (CDDP). An MTT assay was used to determine the cytotoxic effects of rapamycin on MG63 osteosarcoma cells. The cell cycle was assessed using a flow cytometry analysis subsequent to staining the DNA with propidium iodide. The mitochondrial membrane potential (Δψ) was measured using the fluorescent probe, JC-1. Western blot analysis was used to determine the expression of the proteins that are involved in apoptosis and autophagy, including p53, p62, light chain 3 (LC3) and Beclin-1. The viability of the MG63 cells was inhibited following rapamycin or CDDP treatment. The mitochondrial Δψ collapsed following treatment with rapamycin or CDDP. Rapamycin induced cell death and enhanced the effects of the induction of MG63 cell death by CDDP. Rapamycin was observed to induce the death of cancer cells through apoptotic and autophagic mechanisms. Rapamycin may enhance the effects of the activation of autophagy and the induction of apoptosis by CDDP.

Introduction

Osteosarcoma is the most commonly diagnosed primary malignant tumor of the bone (1,2). The contemporary treatment of osteosarcoma requires multidisciplinary therapy, incorporating surgery and systemic chemotherapy (1,3). The prognosis of osteosarcoma patients has significantly improved with the advent of chemotherapy. In the pre-chemotherapy era, when patients underwent surgery as the only form of treatment, the survival rate was <20% (4). Osteoclasts have drawn attention as a therapeutic target in various bone disorders, including osteosarcoma. The osteoclast is the only cell that resors bone and is central to pathological situations, where bone destruction is intricately involved. Osteosarcoma cells are of the osteoblastic lineage. Hence, osteosarcoma is a more ideal candidate for osteoclast-targeted therapy than other primary and metastatic bone tumors. The rapid progress that has been made in understanding the molecular mechanism that regulates osteoclasts has propelled the development of new therapeutic approaches (5).

Autophagy is intricately implicated in health and disease. Autophagy defects play a role in the pathogenesis of numerous diseases, including myopathy, neuronal degeneration, microbial infection, inflammatory bowel disease, aging and cancer (6-11). Studies have demonstrated the functional role of autophagy in various cellular processes and the potential of autophagy modulation as a novel therapeutic strategy for a number of pathological conditions, including cancer (12-14).

Anticancer therapies, including hormonal agents, chemotherapy and irradiation, frequently induce autophagy, in most cases as a prosurvival response potentially contributing to treatment resistance. However, autophagy activation in particular genetic backgrounds and/or the completion of the autophagic process beyond the reversibility of cell viability may also lead to cell death, thus enhancing the efficacy of the treatment (15-18).

The activation of autophagy by the inhibition of the mammalian target of rapamycin (mTOR) may contribute to anti-tumor actions. The present study examined the effects of the mTOR inhibitor, rapamycin, on the activation of autophagy and the contribution of autophagy to the chemosensitivity effects of cis-diamminedichloroplatinum (CDDP) on osteosarcoma MG63 cells.

Materials and methods

Reagents. MG63 osteosarcoma cancer cells were purchased from the Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). RPMI-1640 medium was purchased from Gibco (Rockville, MD, USA) and rapamycin was purchased from Biovision Technology (Milpitas, CA, USA). Fetal bovine serum was purchased from Hangzhou Sijiqing Biological Engineering Material Co., Ltd., (Hangzhou, Zhejiang, China) and L-glutamine and MTT were purchased from Sigma (St Louis, MO, USA). Rabbit monoclonal anti-p53, -p62, -Beclin-1 and -light chain 3 (LC3) antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA).

Drug preparation. Rapamycin (Biovision Technology) was diluted in DMSO to create a stock solution that was stored according to the manufacturer's instructions. The final concentrations of the rapamycin and CDDP solutions used were 5 and 2 µmol/l, respectively. This concentration of rapamycin was selected on the basis of our experiments on the MG63 cells.

Cell culture and viability assay. The MG63 cells were maintained in RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum and 0.03% L-glutamine, and incubated in a 5% CO₂ atmosphere at 37°C. The cells that were in a mid-log phase were used in the experiments. The cell viability was assessed using an MTT assay. To determine the time-course of the response of the MG63 cells to rapamycin and CDDP, the MG63 cells were plated into 96-well microplates (7x10⁴ cells/well). Rapamycin (5 µmol/l) and CDDP (2 µmol/l) was added to the culture medium and the cell viability was assessed using the MTT assay at 24, 48 and 72 h following the drug treatment. MTT solution (Sigma) was added to the culture medium (500 µg/ml final concentration) for 4 h prior to the end of treatment and the reaction was stopped by the addition of 100 µl 10% acidic SDS. The absorbance value (A) at 570 nm was read using an automatic multwell spectrophotometer (Bio-Rad, Richmond, CA, USA). The percentage of dead cells was calculated as follows: Cell death (%) = (1 - A of experimental well / A of positive control well) x 100.

Detection of mitochondrial membrane potential (Δψ). The mitochondrial Δψ was determined using the KeyGen Mitochondrial Membrane Potential Sensor kit (KeyGen, Nanjing, Jiangsu, China). The mitosensor dye aggregates in the mitochondrial membranes of healthy cells and emits red fluorescence against a green monomeric cytoplasmic background staining. However, in cells with a collapsed mitochondrial Δψ, the dye is not able to accumulate in the mitochondria and remains as monomers throughout the cells emitting green fluorescence (19). Briefly, the MG63 cells were incubated with rapamycin and CDDP in 24-well plates for the indicated times and then pelleted, washed with PBS and resuspended in 0.5 ml diluted mitosensor reagent (1 µmol/ml in incubation buffer). Subsequent to incubating the cells with mitosensor reagent for 20 min, 0.2 ml incubation buffer was added and the cells were centrifuged and then resuspended in 40 µl incubation buffer. Finally, the cells were washed and resuspended in 1 ml PBS for flow cytometry analysis.

Detection of the cell cycle. To analyze the effects of rapamycin on cell apoptosis progression, the MG63 cells were incubated

with rapamycin and CDDP. The cells were harvested using 0.25% trypsin, washed with PBS, counted and adjusted to a concentration of 1x10⁶ cells/ml. The cells were fixed in 70% ethanol, treated with 100 mg/l RNase at 37°C for 30 min and then stained with 50 mg/l propidium iodide (Sigma) for 30 min. The cells were analyzed using flow cytometry (Epics XL; Beckman Coulter, Fullerton, CA, USA).

Total cell protein extraction and western blot analysis. For the extraction of the total cell proteins, the cells were washed with pre-cooled PBS and subsequently lysed in a pre-cooled RIPA lysis buffer containing 50 mM Tris-HCl (pH 7.4) 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.25% sodium deoxycholate, 0.1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 50 mM sodium pyrophosphate, 1 mM Na₂VO₄, 1 mM NaF, 5 mM EDTA, 5 mM EGTA and a protease inhibitor cocktail. Cell lysis was performed on ice for 30 min. Clear protein extracts were obtained by centrifugation at 12,000 x g for 30 min at 4°C. The protein extraction procedure from the MG63 cells was performed as previously described. The protein concentration was determined using a Bradford protein assay kit (KeyGen). The proteins were resolved on 8.5% polyacrylamide gels and subsequently transferred onto nitrocellulose membranes. For immunoblotting, the nitrocellulose membranes were incubated overnight at 4°C with specific antibodies recognizing the target proteins. The membranes were then incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:3,000) for 1 h at room temperature and subsequently analyzed using an enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech, Amersham, UK) and visualized by autoradiography, β-actin proteins (1:5,000; Sigma) were used as loading controls.

Statistical analysis. All data are presented as the mean ± SD. The statistical analysis was performed using an ANOVA followed by Dunnett's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Rapamycin inhibits cell viability and enhances the effects of CDDP-induced tumor cell growth inhibition. In the present study, rapamycin reduced MG63 cell viability in a time-dependent manner. The MTT assays revealed that following 24 h of treatment, the rate of inhibition reached 32±1.76% at the dose (5 µmol/l) used. The rate of inhibition increased when the incubation time was prolonged, reaching 44±2.09% at 48 h and 52±2.87% at 72 h following the treatment (Fig. 1). CDDP (2 µmol/l) was used to assess the clinical value of the mTOR inhibitor in the treatment of the tumor and to test the synergistic inhibitory effect of the mTOR inhibitor on the growth of the cells in combination with a chemotherapy drug. Rapamycin was shown to have an increased effect when used in combination with CDDP compared with when used alone (Fig. 1). Thus, rapamycin inhibited the proliferation of the MG63 cells and enhanced the chemosensitivity of CDDP.

Rapamycin induces mitochondrial dysfunction and enhances the effects of CDDP-induced mitochondrial dysfunction.
In the present study, the mitochondrial Δψ was examined using the fluorescent dye, JC-1. A collapse in the mitochondrial Δψ was detected as early as 6 h after rapamycin or CDDP treatment, as indicated by an increased emission of green fluorescence. This change reached a maximum level following 24 h of rapamycin treatment or 12 h of CDDP treatment (Fig. 2). A collapse in mitochondrial Δψ indicates cell apoptosis or necrosis. Rapamycin used in combination with CDDP, rather than used alone, induced mitochondrial dysfunction and activated cell apoptosis in the MG63 cells. The present results demonstrate that rapamycin enhanced the effects of CDDP-induced mitochondrial dysfunction in the MG63 cells.

Rapamycin increases the expression of p62 and LC3 and enhances the effects of CDDP-activated autophagy. To

Figure 1. Viability of MG63 cells exposed to rapamycin or CDDP treatment. Reduced viability of MG63 cells was observed following rapamycin or CDDP treatment. The MG63 cells (7x10^4 cells/ml) were cultured with rapamycin or CDDP for the indicated times and cell viability was analyzed using an MTT assay. Rapamycin had an increased effect when used in combination with CDDP compared with when used alone. Rapamycin inhibited the proliferation of the MG63 cells and enhanced the chemosensitivity of CDDP. Data are presented as mean ± SD of three independent experiments. *P<0.05 vs. the rapamycin alone treatment group. CDDP, cis-diamminedichloroplatinum.

Figure 2. Mitochondrial dysfunction was induced following rapamycin or CDDP treatment. The MG63 cells were incubated with 5 µmol/l rapamycin or 2 µmol/l CDDP for the indicated times. (A) Control, (B) 6 h, (C) 12 h and (D) 24 h after rapamycin treatment (n=3). (E) 12 h with CDDP treatment. (F) 12 h with rapamycin and CDDP treatment. CDDP, cis-diamminedichloroplatinum.

Figure 3. Apoptosis was induced following rapamycin or CDDP treatment. MG63 cells were incubated with 5 µmol/l rapamycin or 2 µmol/l CDDP for the indicated times. (A) Control, (B) 6 h, (C) 12 h and (D) 24 h following rapamycin treatment (n=3). (E) 12 h with CDDP treatment. (F) 12 h with rapamycin and CDDP treatment. CDDP, cis-diamminedichloroplatinum.

Rapamycin induces apoptosis and enhances the effects of the CDDP-induced apoptosis of MG63 cells. The effect of rapamycin on the cell apoptosis progression of the MG63 cells was studied following 6, 12 and 24 h of exposure to 5 µmol/l rapamycin. The flow cytometry analysis indicated that rapamycin induced cell apoptosis following 6, 12 and 24 h of treatment. There was a significant difference between the 5µmol/l rapamycin and CDDP groups and the control group at 12 h. When the cells were treated with rapamycin and CDDP at 12 h, the apoptosis of the MG63 cells was significantly increased than when rapamycin was used alone (Fig. 3). The results indicated that rapamycin enhanced the effects of inducing MG63 cell apoptosis by CDDP.

Rapamycin increases the expression of p62 and LC3 and enhances the effects of CDDP-activated autophagy. To
distinguish the specific inhibition of mTOR-mediated cell proliferation from autophagy, the expression of the autophagic proteins, LC3 and p62, was measured following treatment with 5 μmol/l rapamycin or 2 μmol/l CDDP. As shown in Fig. 4A, the expression of p62 in the MG63 cell line was activated by rapamycin or CDDP treatment, and rapamycin may have enhanced the effects of CDDP-activated autophagy. As shown in Fig. 4B, western blotting analysis was used to detect the protein levels of LC3-I and LC3-II. The results revealed that the levels of LC3, particularly LC3-II, had increased, leading to an increased ratio of LC3-II/LC3-I following rapamycin or CDDP treatment. Rapamycin may have thus enhanced the effects of CDDP-activated autophagy. These results suggest that rapamycin may induce tumor cell apoptosis by regulating p62 and LC3II.

Rapamycin upregulates p53 and Beclin-1 and enhances the effects of CDDP in the upregulation of p53 and Beclin-1. To distinguish the specific inhibition of mTOR-mediated cell proliferation from autophagy and apoptosis, the expression of the autophagic and apoptotic proteins, p53 and Beclin-1, was measured following treatment with rapamycin or CDDP. As shown in Fig. 5A, the expression of Beclin-1 in the MG63 cell line was activated by rapamycin or CDDP treatment and rapamycin may have enhanced the effects of CDDP-induced autophagy and apoptosis. As shown in Fig. 5B, the expression of p53 in the MG63 cell line was also upregulated and rapamycin may have enhanced the effects of CDDP-induced apoptosis. These results suggest that rapamycin may induce tumor cell apoptosis by regulating Beclin-1 and p53.

Discussion

The tumor suppressor, p53, plays a central role in sensing various genotoxic stresses. p53 is known to play significant roles in apoptosis by regulating the expression of proapoptotic proteins (20,21). The present study demonstrated that as an inhibitor of autophagy, rapamycin significantly upregulated the levels of p53, indicating that apoptosis may be triggered by CDDP. The mitochondrial Δψ collapse was shown to induce cell death following rapamycin treatment. The study revealed that rapamycin induced mitochondrial dysfunction in the MG63 cells. Mitochondria play a central role in regulating cell death and survival. Diverse proapoptotic stimuli act on mitochondria, triggering mitochondrial Δψ collapse, cytochrome c release and caspase activation. The mitochondrial permeability transition (MPT) represents a significant event in initiating apoptotic cell death (22).

Increasing evidence suggests that autophagy plays significant roles in tumor cell growth, differentiation and the response to anti-tumor drugs (23). Numerous classical anti-tumor drugs have now been identified to exert their cytotoxic actions by autophagic mechanisms (24–26). In the present study, the inhibition of mTOR by rapamycin resulted in a significant increase in the levels of p62, LC3 and Beclin-1, and a particularly increased production of LC3-II. LC3 is an autophagosomal ortholog of yeast Atg8. LC3 has been best characterized as an autophagosomal marker in mammalian autophagy and the levels of LC3 may also reflect the levels of LC3 in initiating apoptotic cell death (27). Beclin-1 is the mammalian ortholog of the yeast ATG6-Vps30 gene. p62 is also present in protein aggregates that are positive for ubiquitin and microtubule-associated protein-1 (MAP1) LC3, a well-characterized marker of a cellular process known as autophagy. p62 is believed to be the link between polyubiquitinated proteins and autophagy (28). The present results suggest that autophagy inhibited by rapamycin may contribute to cell apoptosis.

In summary, the present study revealed a new mechanism associated with mTOR inhibition that triggered the impairment of cell proliferation and the induction of the cell death of cancer cells. The inhibition of mTOR increases the expression of p53 and induces the expression of the proapoptotic and autophagic proteins, p62, LC3 and Beclin-1. Rapamycin induced the death of cancer cells through apoptotic and autophagic mechanisms and may have enhanced the effects of CDDP on activating autophagy and inducing apoptosis. Further investigation of the association between autophagy activation and the anti-tumor effects of mTOR inhibitors may unveil new strategies for tumor therapy.
References

1. Raymond AK, Ayala AG and Knuutila S: Conventional osteosarcoma. In: World Health Organization Classification of Tumors. Fletcher CDM, Unni KK and Mertens F (eds). 4th edition. IARC Press, Lyon, France, pp264‑270, 2002.

2. Tan IZ, Schlicht SM, Powell GI, et al: Multidisciplinary approach to diagnosis and management of osteosarcoma-a review of the St Vincent's Hospital experience. Int Semin Surg Oncol 3: 38, 2006.

3. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341‑346, 2007.

4. Marcove RC, Miké V, Hajek JV, Levin AG and Hutter RV: Osteogenic sarcoma under the age of twenty ‑ one. A review of one hundred and forty‑five operative cases. J Bone Joint Surg Am 52: 411‑423, 1970.

5. Akiyama, T, Dass, CR and Choong PF: Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone‑resorbing activity, and apoptosis pathway. Molecular Cancer Ther 7: 3461‑3469, 2008.

6. Malicdan MC, Noguchi S, Nonaka I, Saftig P and Nishino I: Lysosomal myopathies: an excessive build‑up in autophagosomes is too much to handle. Neuromuscul Disord 18: 521‑529, 2008.

7. Winslow AR and Rubinsztein DC: Autophagy in neurodegeneration and development. Biochim Biophys Acta 1782: 723‑729, 2008.

8. Orvedahl A and Levine B: Eating the enemy within: autophagy in infectious diseases. Cell Death Differ 16: 57‑69, 2009.

9. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, et al: A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456: 259‑263, 2008.

10. Saitoh T, Fujita N, Iang MH, Uematsu S, Yang BG, Sato T, et al: Loss of the autophagy protein Atg16l1 enhances endotoxin‑induced IL‑1beta production. Nature 456: 264‑268, 2008.

11. Yen WL and Klionsky DJ: How to live long and prosper: autophagy, mitochondria and aging. Physioloogy (Bethesda) 23: 248‑262, 2008.

12. Mathew R, Karantza‑Wadsworth V and White E: Role of autophagy in cancer. Nat Rev Cancer 7: 961‑967, 2007.

13. Carew JS, Nawrocki ST and Cleveland JL: Modulating autophagy for therapeutic benefit. Autophagy 3: 464‑467, 2007.

14. Chen N and Karantza‑Wadsworth V: Role and regulation of autophagy in cancer. Biochim Biophys Acta 1793: 1516‑1523, 2009.

15. Al‑Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP and Khanna KK: Harnessing the complexity of DNA‑damage response pathways to improve cancer treatment outcomes. Oncogene 29: 6085‑6098, 2010.

16. Gewirtz DA: Autophagy as a mechanism of radiation sensitization in breast tumor cells. Autophagy 3: 249‑250, 2007.

17. John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, et al: Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res 68: 7855‑7863, 2008.

18. Buytaert E, Callewaert G, Vandenhende JR and Agostinis P: Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2: 238‑240, 2006.

19. Petronilli V, Miotto G, Cantor M, et al: Imaging the mitochondrial permeability transition pore in intact cells. Biofactors 8: 263‑272, 1998.

20. Moll UM and Zaike A: Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 493: 65‑69, 2001.

21. Erster S, Mihara M, Kim RH, Petrenko O and Moll UM: In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24: 6728‑6741, 2004.

22. Hirsch T, Marzo I and Kroemer G: Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep 17: 67‑74, 1997.

23. Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891‑2906, 2004.

24. Bursch W, Ellinger A, Kienzl H, Török L, Pandey S, Sikorska M, et al: Active cell death induced by the anti‑estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF‑7) in culture: the role of autophagy. Carcinogenesis 17: 1595‑1607, 1996.

25. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide‑induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448‑457, 2004.

26. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 439‑444, 2001.

27. Kabeya Y, Mizushima N, Ueno T, et al: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720‑5728, 2000.

28. Kirkin V, McEwan DG, Novak I and Dikic I: A role for ubiquitin in selective autophagy. Mol Cell 34: 259‑269, 2009.